FDA Approves Gene Therapy Marne-Cel for Children with Severe Immunodeficiency
FDA has approved Marne-Cel, the first stem cell-based gene therapy for children with severe leukocyte adhesion deficiency type I. In trials, transplant-free survival was 100%.
Marne-Cel and Fatal Leukocyte Adhesion Deficiency: How Rocket Pharmaceuticals Turned Three FDA Rejections into a Strategic Breakthrough
On March 26, 2026, the FDA approved marnetegragene autotemcel (marne-cel, Kresladi) from Rocket Pharmaceuticals—the first stem cell-based gene therapy for children with severe leukocyte adhesion deficiency type I (LAD-I). The indication covers patients with biallelic ITGB2 variants who lack an HLA-matched sibling for allogeneic transplantation. In a phase 1/2 clinical trial, transplant-free survival was 100%.
Headlines captured the fact: the first targeted drug, a miraculous rescue, a breakthrough. But the real story of this approval is not about medicine—it's about how a small biotech turned a series of regulatory rejections into a strategic asset and laid the foundation for a business model that will redefine the economics of ultra-orphan gene therapy.
The Essence: What's Really Happening
LAD-I is a disease most doctors have never even heard of. A mutation in the ITGB2 gene prevents leukocytes from leaving the bloodstream to enter tissues, leaving a child defenseless against bacterial and fungal infections. Without a bone marrow transplant, mortality reaches 75% in the first two years of life. Allogeneic hematopoietic stem cell transplantation can be curative but carries the risk of severe graft-versus-host disease and requires a compatible donor. Fewer than 400 cases are registered worldwide, with about 50 people living with this diagnosis in the US. The market is so small that most pharma companies wouldn't even consider development. Rocket Pharmaceuticals did.
The drug marne-cel is made from the patient's own hematopoietic stem cells, which are genetically modified with a lentiviral vector carrying a functional copy of ITGB2 and returned to the body after myeloablative conditioning with busulfan. One infusion. Lifelong effect. Nine treated children in the NCT03812263 study—all alive at a median follow-up of 24 months. The rate of infectious hospitalizations dropped by 74%, prolonged hospitalizations by 82%, and serious infections by 85%. No cases of graft failure. No serious adverse events related to gene therapy.
Timeline and Context: The Path Through Three Rejections
The story of this approval is a chronicle of regulatory siege that few would have survived with an intact budget. The first BLA was submitted in October 2023 and accepted by the FDA with priority review. In June 2024, the FDA responded with a refusal—a Complete Response Letter requesting additional information on chemistry, manufacturing, and controls (CMC). Rocket downsized and resubmitted the application in October 2024. The PDUFA date was set for March 28, 2026.
In parallel, the company withdrew its European application for another product—gene therapy RP-L102 for Fanconi anemia—for commercial, not clinical, reasons, to concentrate resources on Kresladi. This was a decision the industry called "betting the farm": Fanconi anemia is a larger market, LAD-I is nearly zero. Rocket chose zero. Because that's where they could win.
Who Wins and Who Loses
Rocket Pharmaceuticals wins. The company didn't just get approval—it got a Rare Pediatric Disease Priority Review Voucher (PRV). The market for such vouchers is robust, with recent sales in the $200 million range. With Rocket's market cap around $331 million, selling the voucher could instantly double the company's value without diluting shareholders. That, not drug sales, is the main financial ace. Commercial shipments of marne-cel will begin in Q4 2026, with reimbursement starting in 2027 due to the 4-5 month cycle from cell collection to infusion.
Patients with LAD-I and their families win. For them, the prospect of "either find a donor or bury your child before age two" disappears. This isn't even an improvement in therapy—it's a shift from imminent death to a normal childhood. Professor Donald Kohn from UCLA, the lead investigator in the US, states plainly: "All these children are healthy, without serious infections or inflammatory skin lesions. They are living normal childhood lives." The economic impact is also colossal: allogeneic HSCT costs hundreds of thousands of dollars, massive antibiotic therapy tens of thousands per year, and each day in the ICU thousands. A single infusion removes this entire burden.
The lentiviral platform as a whole wins. The approval of marne-cel confirms that ex vivo gene therapy with lentiviral vectors is safe and effective for immunodeficiencies. Rocket is already using the same platform for Fanconi anemia and pyruvate kinase deficiency.
Other orphan biotechs—for now—lose. Rocket set a precedent: you can get rejected three times, downsize twice, and still reach approval. This raises the bar for investor expectations but also raises the question: if Rocket could do it, why can't others? Companies that shut down after a first rejection now look like they gave up too early.
Critics of gene therapy pricing—indirectly—lose. With 50 patients in the US and the need to recoup hundreds of millions in development costs, the price tag for marne-cel will inevitably fall in the $2-3 million per patient range, reigniting public debate about access to orphan drugs. Rocket has not yet officially announced a price.
What the Media Isn't Saying
Insight: Accelerated approval is not a weakness but a strategy. The FDA granted accelerated approval based on a surrogate marker—increased expression of CD18 and CD11a on neutrophil surfaces. In typical oncology, this is considered a "weak" type of approval with risk of withdrawal. But in the case of LAD-I, it's a brilliant move. Confirming clinical benefit doesn't require a new study—just long-term follow-up of already treated patients and a post-marketing registry. Rocket essentially got full commercial clearance without needing to enroll new cohorts. This is a blueprint for all ultra-orphan programs: small single-arm trial + surrogate endpoint + registry = accelerated approval with minimal post-marketing obligations.
Insight two: CMC issues as a competitor filter. The two FDA rejections were not about efficacy or safety but about manufacturing processes. Few admit this publicly, but CMC for autologous gene therapy is hell. Each batch is unique because it's made from a specific patient's cells. Standardization with nine patients in a study is a statistical nightmare. That Rocket passed this filter creates a barrier to entry for competitors: anyone wanting to replicate this path will face the same CMC requirements and spend 3-4 years just meeting them. Rocket gained a temporary monopoly not on the molecule but on manufacturing expertise.
Insight three: Funding through dying children—the bitter reality of the orphan market. Rocket's success in raising funds was directly tied to the drama of the indication. LAD-I kills children in infancy. Allogeneic HSCT without a compatible donor is almost certain death. The story of a child who "will die without therapy" is the most powerful argument for the FDA, investors, and payors. Rare diseases with high pediatric mortality become commercially attractive precisely because of this emotional and ethical desperation. This isn't cynicism; it's a structural feature of the market: the more terrifying the disease and the fewer patients, the easier to get approval and the higher the price you can set.
Forecast: Next 30 Days and 90 Days
In the next 30 days, expect an announcement of Kresladi's price. The range will be $2.2-2.8 million per single infusion. Simultaneously, Rocket will begin negotiations with centers certified for autologous gene therapy—there are no more than 15-20 in the US, and onboarding each requires months of logistical preparation. Also likely is an announcement of the PRV sale: with a market cap of $331 million, liquidity from selling the voucher for $150-200 million is an immediate and non-dilutive way to strengthen the balance sheet.
In the 90-day outlook, Rocket, in my estimation, will announce the hiring of a specialized commercial support team for transplant centers. The "vein-to-vein" model—from cell collection from the patient to return of the modified product—requires coordination that doesn't exist in standard drug distribution. Each treated patient in 2027 will cost the company tens of thousands of dollars just in logistics.
The most interesting scenario is that Rocket uses marne-cel as a proof-of-concept to relaunch the Fanconi anemia program. If the lentiviral ex vivo therapy platform is validated by FDA approval, bringing back RP-L102 becomes a matter of time, not possibility. I estimate a 70% probability of resubmitting a BLA for Fanconi anemia by the end of 2027.
And the main strategic takeaway for the industry: FDA CMC rejections should no longer be viewed as a catastrophe. They are a filter. Those who pass through it gain a market without competition. Rocket passed. And now it owns not just a drug but an entire class of diseases where it sets the rules of the game.
— Editorial Team
